DAFTAR PUSTAKA
1. Risk score profiles. Framingham Heart Study ( Internet). 2012.
(cited 2012 Feb 5) Available from:
2. Silvia Loraine, 2006 a. Penyakit Aterosklerotik Koroner.
Patofisiologi Konsep Klinis Proses-Proses Penyakit Volume I. Edisi
VI. Penerbit Buku Kedokteran EGC Jakarta hal 576-612
3. Price SA. Prosedur diagnostik penyakit kardiovaskular. Dalam:
Wijaya C editor. Patofisiologi konsep klinis proses-proses penyakit.
Edisi 4. Jakarta: Penerbit Buku Kedokteran EGC; 1994: 515-523
4. Hollinger I. Mitinach A. Cardiac catheterization and other
radiographic examination. Pediatric Cardiac Anesthesia. 4. ed
Lippincott Williams and Walkins 2005; 7: 112-135
5. Trianti M, Xanthos T, Lacovidou N, et al. Relationship between
individual cardiovascular risk factors and localization of coronary
atherosclerotic lesions. Heart and Lung: The journal of acute and
critical care, 2010
6. Deitcher SR, Rodgers GM.Trombosis and Antitrombotic Therapy.
In: Greer JP, Foerster J, Lukens JN, et al. Wintrobe”s Clinical
Hematology. 11th
7. McKay J, George AM, Shantu M. Kurt G. The atlas of Heart
Disease and Stroke. WHO.Geneva; 2004
ed Lippincott Williams and Wilkins. USA. 2004:
8. Hasan R. Obat – obat anti agregasi trombosit pada PJK, UPF Ilmu
Penyakit Dalam FK – USU / RSUP H. Adam Malik Medan, 1997 : 1
– 5
9. Irmalita. Infark Miokard. Dalam buku ajar Kardiologi. FKUI. Jakarta,
1996:173-77
10. Setiabudy R. Patofisiology thrombosis; dalam hemostasis dan
thrombosis. Patologi Klinik FKUI/ RSCM. Jakarta, 1992:26-35
11. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology, and
determinants. Hemostasis Thrombosis and Vascular Biology.
University of Medicine Birmingham, 2003: 712-23
12. Harjai KJ. Potential New Cardiovascular Risk Factors: Left
Ventricular Hyperthrophy, Homocystein, Lipoprotein (a),
Triglycerides, Oxidative Stress and Fibrinogen. Annal of Internal
Medicine, 1999; 131 (5): 376-86
13. Tarrallo P. Reference Limit of Plasma Fibrinogen. Eur. J. Clin.
Chem. Clin. Biochem, 1992; 30(11): 745-51
14. Stone MC, Thorp Jm. Plasma fibrinogen a major coronary risk
factor; J Roy Coll Gen Prac 1985: 565-9
15. Cooper J, Douglas AS. Fibrinogen Levels as a Predictor of Mortality
in Survivors of Myocardial Infarction. Fibrinolysis Vol.5 no.2,1991:
105-8
16. Lee AJ. Fibrinogen in Relation to Personal History of Prevalent
Coronary Heart Disease and Family History, The Scottisth Heart
Health Study. British Heart Journal, 1993; 69: 338-42
17. Jastrzebska M., Foltynska A., Tourbus-Lisiecka B., Chelstowski K.,
Piechul-Mroz J. et al. Fibrinogen and von Willebrand Factor Levels
in Relation to Lipid Profile and Blood Presure in Children Whose
Fathers Have a History of Premature Myocardial Infarction. Polish
Heart Journal, 2002; 6(5)
18. Green David, Foiles Nancy, Chan Cheeling et al. Elevated
fibrinogen levels and subsequent subclinical atherosclerosis: The
CARDIA Study. Atherosclerosis 202 (2009) 623 – 631
19. Thompson GR. A handbook of Hyperlipidemia. London: Merc &
Co.1990
20. Fargenbaum J. Aterosclerosis 2003. Available from
21. Widjaya DJ. Perkembangan penyelidikan Mutakhir Faktor Risiko
Stroke. Kumpulan Makalah Simposium Continuing Medical
Education The 6th
22. Marcovina SM, Koschinsky ML. Lipoprotein (a): Structure,
Measurement and Clinical Significance In: Rifai N, Warnick RG,
Dominiczak MH. Handbook of Lipoprotein Testing 2009. P: 283 –
313
Perdossi Course on Stroke. Jakarta.1999
23. Karniawati M, Lipoprotein (a). Informasi Laboratorium Prodia. 2000.
24. Packard RR, Libby P. Inflamation in atherosclerosis: from vascular
biology to biomarker discovery and risk prediction. Clin chem..
2008, p: 24 – 28
25. Hansson GK. Inflammation , atherosclerosis and coronary artery
disease. N engl J Med. 2005.p: 1685 – 95
26. Hunziker PR. Bedside quantification of atherosclerosis severity for
cardiovascular risk stratification: a prospective cohort study, J Am
Coll Cardiol. 2002; 39:702-9
27. Feskens EJ, Kromhouts D. Glucosa tolerance and risk of
cardiovascular disease: the Zutphen study. J Clin Epidemiol. 2002;
45: 1327 – 34
28. Jennings PE. The mechanism of diabetic macroangiopathy.
Diabetographia. International Medical Publication 2003; 11: 4 – 6
29. Osterud B, Bjorklid E. Role of monocytes in atherogenesis.
Department of Biochemistry, Institude of Medical biology, Faculty
of Medicine University of Tiomso, Norway. 2003. P: 1077 – 8
30. Hills L.D. and Braundwald; E: Coronary - artery Spasm. N. Engl. J.
Med 2001; 299: 695
31. Davies, M. J. Intramyocardial platelets aggregation in patient with
unstable angina suffering sudden ischemic cardiac death.
Circulation. 2001; 73: 418
32. Fahey VA and Riegel BJ: Advances in diagnostic testing for
33. Mannering D, Bennett ED, Ward DE, Dawkins K, Dancy M,
Valantine H, et al. Accurate detection of triple vessel disease in
patients with exercise induced ST segment depression after
infarction. Br Heart J; 1987:57:133-8
34. Goodnight SH., Hathaway WE. Abnormalities of fibrinogen In
Disorders of Hemostasis and Trombosis A Clinical Guide. Ed. 2. Mc
Graw Hill companies Ne 2001; 18: 175 – 78
35. Greenberg CS., Orthner CL. Blood Coagulation and Fibrinolysis in
Wintrobe’s Clinical Haematology 9th
36. Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P,
Heslop H. Hematology: Basic principles and practice. 5rd ed.
Philadelphia 2007: Churcill Livingstone Inc. p: 1827, 2046-7
ed. Lippincott Williams &
Wilkins. Philadelphia, 2002:495
37. Mosesson MW. Fibrinogen & Fibrin Polymerization: The Binding
Events That Accompanya Fibrin Generation and Fibrin Clot
Assembly. Blood Coagulation Fibrinolisis. 1997. P : 257 - 67
38. Giangrande PLF. Fibrinogen Deficiency 2010, available at:
39. Ziedins KB, Orfeo T, Jenny NS, et al. Blood Coagulation and
Fibrinolisis. In: Greer JP, et al, (Eds). Wintrobe’s Clinical
Haematology, 11 th
40. Browse MS. Fibrinogen Medical Encyclopedia, Verimed heathcare
Network 2011
41. Cote HCF, Lord ST, Pratt KP.y – Chain Dysfibrinogemias:
Molecular Structure – Function Relationship of naturally Occuring
Mutations in the y Chain of Human Fibrinogen. The Journal Of The
American Society of Haematology, Oct 1998:92(7)
42. Roberts HR, Monroe DM, Hoffman M. Molecular Biochemistry Of
The Coagulation Factors and Pathways of Haemostasis. In: Beutler
E, Litchman MA, Coller BS, Kipps TJ, Eds. Williams Haematology,
6 th
43. Richard A, Mc Person. Specific Protein. In: Davey FR, Nakamura
RM Eds. Henry JB. Clinical Diagnosis by Laboratory Methods
Philadelphia, 19
ed. New York: Mc Graw Hill, 2001: :1423-5
th
44. Ernst E, Resch KL. Fibrinogen as a Cardiovascular Risk factor A
Meta – Analysis and Review of the Literature. European heart
journal 1993; 118: 956-63
ed WB Saunders Company, 1996;237-240
45. Stecc JJ, Silbershatz H. Association of Fibrinogen with
Cardiovascular Risk Faktor and Cardiovascular diseases In the
Framingham Offspring Population. Circulation 2000; 1634-38
46. Smith EB. Fibrinogen, fibrin and fibrin degradation product
inrealition to atherosclerosis. Clin Haematol 1986; Vol 15: 355-70
47. Ross, Epstein FH. Atherosclerosis an inflammatory disease. N Engl
48. Kannel WB, Wolf PA, Castell, Agostino RB. Fibrinogen and risk of
cardiovascular diseases. The Framingham Study In The Journal of
the American Medical Association 1987; Vol.258: 1-15
49. Nito I. Correlation between Cortisol level and myocardial infarction
mortality among ICCU patients during first seven days in hospital.
Acta Medica Indosianna, 2004: 8-10
50. Frohlich M, Sund M. Independent association of various smoking
characteristics with markers of systemic inflammation in men In
European Heart Journal 2003; Vol 24: 1365-72
51. Martin AS, Steininger CA, Koepke J. Routine and special laboratory
evaluation of coagulation In Clinical hematology. Principles,
Procedurs, Correlation Ed 2. Lippincott Philadelphia New York
1998; 49: 639-40
52. Wood S. What’s “ normal ? “ Little consensus on CAD extent,
severity among Ontario angiographers 2011
53. Bayes-Ganis A, maleo J, Santalo M, Oliver A, Guindo J, Badimon L,
et al. Early diagnostic marker of Coronary ischaemia in patients with
chest pain. Am Heart J 2000; 140: 379-84
54. Greenberg CS, Orthner CL. Blood Coagulation and Fibrinolysis in
Wintrobe’s Clinical Hematology 9th ed.Lippincott Williams and
55. Gabay C. and Kushner I. Acute-Phase Proteins and other Systemic
Responses to Inflammation. The New England Journal of Medicine,
1999; 340(6): 448-454
56. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P,
Arveiler D, Fruchart JC, Ducimetiere P.C-reactive protein,
interleukin-6, and fibrinogen as predictors of coronary heart
disease: The PRIME study. Arterioscler Thromb Vasc Biol 2003;23:
1255-1261
57. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E. Impact of
C-reactive protein and fibrinogen on cardiovascular prognosis in
patients with stable angina pectoris: the AtheroGene study.
58. Koh SCL, Biol C, Mibiol. Diagnostic Approach to Hypercoagulation
and enhanced Fibrynolisis presented at the 8th International
Congres of The Asian Society of Clinical Pathology and Laboratory